Search

Displaying results 7181 - 7190 of 7399 in total
  1. Drug

    Cinolazepam

    go.drugbank.com/drugs/DB01594
    Investigational

    Cinolazepam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant activity. It is not approved in Canada or America.

    Synonyms: 7-chloro-5-(o-fluorophenyl)-2,3-dihydro-3-hydroxy-2-oxo-1H-1,4-benzodiazepine-1-propionitrile
  2. Drug

    KOS-2187

    go.drugbank.com/drugs/DB05946
    Experimental

    KOS-2187, a novel erythromycin-based motilin agonist, or motilide, as a clinical candidate for the treatment of gastrointestinal motility disorders such as gastroparesis and gastroesophageal reflux disease (GERD).

  3. Drug

    Imisopasem manganese

    go.drugbank.com/drugs/DB04976
    Investigational

    M40403 is a low molecular weight, synthetic manganese containing superoxide dismutase mimetic (SODm) that selectively removes superoxide anion.

  4. Drug

    Quercetin

    go.drugbank.com/drugs/DB04216
    Investigational

    Quercetin is a flavonol widely distributed in plants. It is an antioxidant, like many other phenolic heterocyclic compounds. Glycosylated forms include RUTIN and quercetrin.

    Synonyms: poly (lactide-co-glycolide)-polyethylene glycol nanoparticles encapsulating quercetin
  5. Drug

    Levilimab

    go.drugbank.com/drugs/DB16387
    Investigational

    Levilimab is under investigation in clinical trial NCT04227366 (Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis).

  6. Drug

    Tezampanel

    go.drugbank.com/drugs/DB06354
    Investigational

    Tezampanel is an AMPA receptor antagonist.

  7. Drug

    PRX-07034

    go.drugbank.com/drugs/DB05993
    Experimental

  8. Drug

    Cenisertib

    go.drugbank.com/drugs/DB06347
    Investigational

    Cenisertib is an aurora kinase inhibitor.

  9. Drug

    Teprenone

    go.drugbank.com/drugs/DB15955
    Investigational

  10. Drug

    Vatalanib

    go.drugbank.com/drugs/DB04879
    Investigational

    Vatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors. Vatalanib is under investigation for the treatment of solid tumors.